Protalix BioTherapeutics, Inc.
Close on Oct 19, 2026
- Market cap
- $211.35M
- P/E (TTM)
- 11.1
- Dividend yield
- –
Earnings
Next report expected Nov 12, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 12, 2026 | Before market open | – | $0.05 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 13, 2026 | Before market open | – | $0.22 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 18, 2026 | Before market open | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 13, 2025 | Before market open | $17.90M | $0.03 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 14, 2025 | Before market open | – | $0.00 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 9, 2025 | Before market open | – | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 17, 2025 | Before market open | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 14, 2024 | Before market open | – | $0.03 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 14, 2024 | Before market open | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 10, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 14, 2024 | Before market open | – | – | – |
Company guidance
Outlook given with results on Aug 12, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| Total revenue | full-year 2026 | $78.00M to $83.00M | Raised |
| revenues from sales of Elfabrio ® without milestones | Full ‑ year 2026 | $33.00M to $35.00M | Lowered |
| revenues from sales of Elelyso ® | Full ‑ year 2026 | $20.00M to $23.00M | Lowered |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Protalix BioTherapeutics filed with the SEC
Protalix BioTherapeutics Reports Second Quarter 2026 Financial and Business Results
Results of operations · EX-99.1 to Form 8-K
C O R P O R A T E P R E S E N T A T I O N
Regulation FD disclosure · EX-99.1 to Form 8-K
Protalix BioTherapeutics Reports First Quarter 2026 Financial and Business Results
Results of operations · EX-99.1 to Form 8-K
Protalix BioTherapeutics Reports Fiscal Year 2025 Financial and Business Results
Results of operations · EX-99.1 to Form 8-K
C O R P O R A T E P R E S E N T A T I O N
Regulation FD disclosure · EX-99.1 to Form 8-K
Chiesi Global Rare Diseases and Protalix BioTherapeutics
Other events · EX-99.1 to Form 8-K
Protalix BioTherapeutics Letter to Stockholders
Regulation FD disclosure · EX-99.1 to Form 8-K
Third Quarter 2025 Financial and Business Results
Results of operations · EX-99.1 to Form 8-K
C O R P O R A T E P R E S E N T A T I O N
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Chiesi Global Rare Diseases and Protalix Biotherapeutics Acknowledge CHMP Negative Opinion on Every Four Week Dosing Regimen of
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Second Quarter 2025 Financial and Business Results
Results of operations · EX-99.1 to Form 8-K
Protalix BioTherapeutics Reports First Quarter 2025
Results of operations · EX-99.1 to Form 8-K
Protalix BioTherapeutics Reports Fiscal Year 2024 Financial and Business Results
Results of operations · EX-99.1 to Form 8-K
Protalix BioTherapeutics Issues 2025 Letter to Stockholders
Regulation FD disclosure · EX-99.1 to Form 8-K
Third Quarter 2024 Financial and Business Results
Results of operations · EX-99.1 to Form 8-K
Protalix BioTherapeutics to Present Phase I PRX-115 Data
Regulation FD disclosure · EX-99.1 to Form 8-K
Second Quarter 2024 Financial and Business Results
Results of operations · EX-99.1 to Form 8-K
Protalix BioTherapeutics Reports First Quarter 2024 Financial and Business Results
Results of operations · EX-99.1 to Form 8-K
Protalix BioTherapeutics Reports Fiscal Year 2023 Financial and Business Results
Results of operations · EX-99.1 to Form 8-K
Protalix BioTherapeutics Issues 2024 Letter to Stockholders
Regulation FD disclosure · EX-99.1 to Form 8-K
Protalix BioTherapeutics Reports Third Quarter 2023 Financial and Business Results
Results of operations · EX-99.1 to Form 8-K
Protalix BioTherapeutics Reports Second Quarter 2023 Financial and Business Results
Results of operations · EX-99.1 to Form 8-K
Protalix BioTherapeutics Issues Letter to Stockholders
Regulation FD disclosure · EX-99.1 to Form 8-K
Protalix BioTherapeutics Announces $20 Million Milestone Payment
Results of operations · Other events · EX-99.1 to Form 8-K
Protalix BioTherapeutics Reports First Quarter 2023 Financial and Business Results
Results of operations · EX-99.1 to Form 8-K
Protalix BioTherapeutics Reports Fiscal Year 2022 Financial and Business Results
Results of operations · EX-99.1 to Form 8-K
Protalix BioTherapeutics Issues 2023 Letter to Stockholders
Regulation FD disclosure · EX-99.1 to Form 8-K
Protalix BioTherapeutics to Delist its Common Stock from the Tel Aviv Stock Exchange
Other events · EX-99.1 to Form 8-K
Protalix BioTherapeutics Reports Third Quarter 2022 Financial and Business Results
Results of operations · Other events · EX-99.1 to Form 8-K
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Resubmission of Biologics License Application to U.S. Food and Drug Administration for Pegunigalsidase Alfa for the Treatment of Fabry Disease
Results of operations · Other events · EX-99.2 to Form 8-K
Protalix BioTherapeutics Reports Second Quarter 2022 Financial and Business Results
Results of operations · EX-99.1 to Form 8-K
Protalix BioTherapeutics Appoints Shmuel “Muli” Ben Zvi, Ph.D.
Executive or director change · Shareholder vote results · Other events · EX-99.1 to Form 8-K
Protalix BioTherapeutics Announces Poster Presentations at the 2022 Program:
Regulation FD disclosure · EX-99.1 to Form 8-K
Protalix BioTherapeutics Reports First Quarter 2022 Financial and Business Results
Results of operations · EX-99.1 to Form 8-K